Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs

A Comprehensive Review of Phase 3 Efficacy and Safety

Paul Bird, MD, PhD,* William Bensen, MD,† Bassel El-Zorkany, MD,‡ Jeffrey Kaine, MD,§ Bernadette Heizel Manapat-Reyes, MD,¶ Virginia Pascual-Ramos, MD,¶ David Witcombe, PhD,# Koshki Soma, MD,** Richard Zhang, PhD,** and Krishan Thirunavukkarasu, MD#

Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We performed a comprehensive review of phase 3 studies of tofacitinib 5 mg twice daily (BID) (approved dose in many countries) in patients with moderate to severe RA and inadequate response to prior disease-modifying antirheumatic drugs.

Methods: A search of PubMed and ClinicalTrials.gov identified 5 studies: ORAL Solo (NCT00814307), ORAL Sync (NCT00856544), ORAL Standard (included adalimumab 40 mg once every 2 weeks, NCT00853385), ORAL Scan (NCT00847613), and ORAL Step (NCT00960440). Efficacy and safety data for tofacitinib 5 mg BID, placebo, and adalimumab were analyzed.

Results: Across the 5 studies, 1216 patients received tofacitinib 5 mg BID 681 received placebo, and 204 received adalimumab. At month 3, tofacitinib demonstrated significantly higher 20%, 50%, and 70% improvement in American College of Rheumatology response criteria (ACR20, ACR50, and ACR70, respectively) response rates, greater improvement in Health Assessment Questionnaire-Disability Index, and a higher proportion of Disease Activity Score-defined remission than placebo. Frequencies of adverse events (AEs), serious AEs, and discontinuations due to AEs were similar for tofacitinib and placebo at month 3; serious infection events were more frequent for tofacitinib. In ORAL Standard, although not powered for formal comparisons, tofacitinib and adalimumab had numerically similar efficacy and AEs; serious AEs and serious infection events were more frequent with tofacitinib.

Conclusions: Tofacitinib 5 mg BID reduced RA signs and symptoms and improved physical function versus placebo in patients with inadequate response to prior disease-modifying antirheumatic drugs. Tofacitinib 5 mg BID had a consistent, manageable safety profile across studies, with no new safety signals identified.

Key Words: efficacy, phase 3, rheumatoid arthritis, safety, tofacitinib

Rheumatoid arthritis (RA) is a chronic and debilitating autoimmune disease associated with considerable morbidity and diminished quality of life and characterized by persistent synovitis, systemic inflammation, and ultimately joint destruction.1,4 Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), such as methotrexate (MTX), are recommended as first-line therapy for RA and are often followed by biologic DMARDs (bDMARDs), such as tumor necrosis factor inhibitors (TNFi), for patients who have an inadequate response (IR).5,6 Earlier and more aggressive use of csDMARDs and the introduction of bDMARDs have improved outcomes for patients.5 However, existing treatment regimens are not effective in all patients, and bDMARDs that require parenteral administration are not universally available.7 In addition, only between 24% and 58% of patients achieve 20% improvement in American College of Rheumatology response criteria (ACR20) after 1 year of treatment.8–11 Despite the variety of targeted bDMARDs available (e.g., TNFi, interleukin inhibitors, and T- and B-cell inhibitors), some patients with active, uncontrolled disease are unable to receive these treatments, additional patients lose clinical response, and some are subject to unacceptable risks.8–10,12 Therefore, a need remains for RA therapies with alternative mechanisms of action to provide patients with additional therapeutic options to manage this chronic and progressive condition.

Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of RA. The JAK family of kinases mediates intracellular signal transduction of cytokines involved in immune regulation and has been linked to regulation of the intensity and duration of inflammatory responses, implicating it in chronic inflammatory diseases, including RA.13,14 Tofacitinib preferentially inhibits signaling via JAK3 and JAK1 with functional selectivity over JAK2.15,16 JAK inhibition blocks the signaling pathways involved in lymphocyte activation, proliferation, and function and may thus modulate the immune response, including reducing inflammation.15,17 Phase 2, dose-ranging, randomized controlled trials
provided sufficient evidence for phase 3 studies of tofacitinib in patients with RA administered as monotherapy or in combination with MTX.\textsuperscript{18–22} Long-term extension (LTE) studies (1 complete and 1 ongoing) to evaluate tofacitinib safety and efficacy over longer periods have been reported for patients who completed phase 2 and 3 studies.\textsuperscript{23,24}

While the phase 3 studies examined 2 separate doses of tofacitinib—5 and 10 mg twice daily (BID)—based on the results of the phase 3 program, tofacitinib has been approved in many countries at a 5-mg BID dose for patients with active RA and an IR or intolerance to prior DMARD treatment.\textsuperscript{25–30} We present a review of tofacitinib 5 mg BID phase 3 data in patients with RA and prior IR to DMARDS (DMARD-IR), in order to provide a comprehensive summary of the efficacy and safety of the widely approved dose in the phase 3 program and to allow comparison of results across the pivotal phase 3 registration studies, including patients with IR to csDMARDS and bDMARDs.

METHODS

Search Strategy

In order to identify all relevant articles to include in this review, a search was conducted in the PubMed and ClinicalTrials.gov databases to identify primary reports of phase 3 randomized controlled trial data for tofacitinib 5 mg BID in patients with active RA and DMARD-IR. We used the search string “tofacitinib AND phase III AND rheumatoid arthritis” to interrogate both databases and identified 38 articles in PubMed and 12 studies in ClinicalTrials.gov. Search results were then assessed for eligibility based on the following inclusion criteria: phase 3 study, patients received tofacitinib 5 mg BID, patients had active RA, and an IR or intolerance to prior DMARD treatment.\textsuperscript{25–30} We present a review of tofacitinib 5 mg BID phase 3 data in patients with RA and prior IR to DMARDS (DMARD-IR), in order to provide a comprehensive summary of the efficacy and safety of the widely approved dose in the phase 3 program and to allow comparison of results across the pivotal phase 3 registration studies, including patients with IR to csDMARDS and bDMARDs.

End Points Evaluated

The phase 3 studies identified in the literature search were reviewed, and data for efficacy and safety end points were extracted. Co-primary end points in all 5 studies were ACR20 rate, least-squares (LS) mean change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI), and Disease Activity Score (DAS)-defined remission (DAS28-4 erythrocyte sedimentation rate [ESR] \(\leq 2.6\)). Radiographic progression, assessed by LS mean change from baseline in modified Total Sharp Score (mTSS), was also a co-primary end point in ORAL Scan. Secondary study end points included ACR50 and ACR70 rates and the proportion of patients with no radiographic progression (change from baseline in mTSS \(\leq 0.5\); ORAL Scan only).

Co-primary end points were measured at month 3 or month 6 and were assessed using a step-down procedure: statistical significance could be claimed only if the prior end point in the sequence met significance requirements. For this review, we primarily evaluated end points at month 3, because this was the most consistent time point across the studies, that is, before placebo-treated patients advanced, so all patients had received their assigned study medication for 3 months. Missing values for binary efficacy variables (e.g., ACR response rates and DAS28-4 [ESR] \(\leq 2.6\)) were imputed using nonresponder imputation. The normal approximation was used to test the treatment difference in proportions. Missing values for HAQ-DI were handled using a linear mixed-effects model with treatment effect assessed from the same model. For mTSS, missing values were imputed using linear extrapolation.

In all 5 studies, safety end points included adverse event (AE) reports, discontinuations due to AEs, serious AEs (SAEs), and clinical laboratory abnormalities. For this review, the most frequent AEs/SAEs were determined by first identifying the AEs/SAEs with the 3 highest percentage values for each study; those AEs/SAEs occurring in 2 or more studies were then identified as the most frequent. In each study, AEs of special interest were analyzed in further detail. These related to safety signals associated with RA treatment and those identified during the tofacitinib clinical development program, including serious infection events.

### TABLE 1. Study Design Information for the 5 Phase 3 Studies

| Study duration | ORAL Solo | ORAL Sync | ORAL Standard | ORAL Scan | ORAL Step |
|----------------|-----------|-----------|---------------|-----------|-----------|
| Previous IR    | 6 mo      | 12 mo     | 12 mo         | 24 mo     | 6 mo      |
| TDAMARD        | DMARD     | DMARD     | Methotrexate  | Methotrexate | TNFi      |
| Study treatments\(a\) | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID |
| Placebo       | Placebo   | Placebo   | Placebo       | Placebo   | Placebo   |
| Background medications | None | csDMARDS | Methotrexate | Methotrexate | Methotrexate |

\(a\)All placebo-treated patients advanced to tofacitinib 5 or 10 mg BID after month 3 or 6, depending on disease activity and according to randomization. cs indicates conventional synthetic; DMARD, disease-modifying antirheumatic drug.
(SIEs), opportunistic infections (OIs), malignancies, lymphomas, lymphocyte and neutrophil levels, and changes in levels of liver transaminases, hemoglobin, lipids, and serum creatinine.

RESULTS

Patients
Across the 5 studies, 1216 patients received tofacitinib 5 mg BD, 681 received placebo, and 204 received adalimumab 40 mg Q2W. Patient selection criteria were similar across the studies, with all 5 studies enrolling patients 18 years or older, with active RA based on the ACR 1987 Revised Criteria, and active disease defined by at least 4 (ORAL Sync) or at least 6 (all other studies) tender/painful joints, at least 4 (ORAL Sync) or at least 6 (all other studies) swollen joints, and ESR greater than 28 mm/h or C-reactive protein greater than 7 mg/L. Additional criteria that applied to ORAL Scan were evidence of 3 or more distinct joint erosions or, if radiographic evidence of joint erosions was unavailable, rheumatoid factor or anti-cyclic citrullinated peptide (anti-CCP) positive. Requirements for prior DMARD use varied across studies, with ORAL Scan and ORAL Standard enrolling MTX-IR patients, ORAL Sync and ORAL Solo enrolling csDMARD-IR or bDMARD-IR patients, and ORAL Step enrolling TNF-IR patients. Patient exclusion criteria relating to AEs and laboratory parameters were similar across studies.

Baseline demographics and disease characteristics were generally well balanced between the treatment arms of individual studies and similar across all 5 studies (Table 2); the only exception was longer disease duration in ORAL Step (TNF-IR) than the other 4 studies (DMARD-IR, MTX-IR) (Table 2).

Efficacy
Across the phase 3 studies at month 3, ACR20 rates were significantly higher with tofacitinib 5 mg BD versus placebo, either as monotherapy or with background DMARDs (Table 3, Fig. 1). Significantly higher ACR20 rates for tofacitinib 5 mg BD versus placebo were observed at the first evaluable time point in each study (week 2 or month 1; Fig. 1). The ACR50 and ACR70 rates followed similar patterns (Table 3). The ACR20 rates were sustained over the remaining study periods for the tofacitinib 5 mg BD group, and similar ACR20 rates were observed after switching for patients who advanced to tofacitinib after 3 or 6 months on placebo (Fig. 1).

The LS mean increases from baseline in mTSS (measured in ORAL Scan only) were numerically greater for placebo-treated patients compared with those receiving tofacitinib 5 mg BD versus placebo, either as monotherapy or with background DMARDs. There were no frequent SAEs (all 0.0%–0.9%) reported in either the tofacitinib 5 mg BD or placebo groups; SAEs were experienced by 2.9% of tofacitinib-treated patients and 4.1% of placebo-treated patients. During the first 3 months of treatment, 4.2% and 3.2% of tofacitinib- and placebo-treated patients discontinued because of AEs, respectively (Fig. 3). In ORAL Standard, tofacitinib- and adalimumab-treated patients reported generally similar AE rates: 52.0% for tofacitinib and 51.5% for adalimumab (patient-years of exposure to month 3 for tofacitinib 5 mg BD vs. adalimumab 40 mg Q2W: 49.0 vs. 49.8; Fig. 3). Although there were few SAEs or discontinuations due to AEs with both tofacitinib (5.9% and 6.9%, respectively) and adalimumab (2.5% and 4.9%, respectively), SAEs and discontinuations due to AEs were numerically higher with tofacitinib than adalimumab.

Overall, the most frequently reported infections for tofacitinib 5 mg BD and placebo across the full reported study periods (6 or 12 months) of the phase 3 studies were bronchitis (n = 14 and n = 10, respectively), herpes zoster (HZ; n = 5 and n = 2, respectively), influenza (n = 8 and n = 5, respectively), nasopharyngitis (n = 47 and n = 19, respectively), upper respiratory tract infection (n = 53 and n = 22, respectively), and urinary tract infection (n = 25 and n = 12, respectively) (patient-years of exposure for tofacitinib 5 mg BD vs. placebo: 1311.5 vs. 696.5). As expected for active treatment, SIEs were numerically more frequent in tofacitinib groups than in placebo groups; 29 patients receiving tofacitinib 5 mg BD and 3 placebo-treated patients reported SIEs. A total of 4 OIs were reported with tofacitinib 5 mg BD: 1 case each of disseminated HZ and Pneumocystis jirovecii pneumonia and 2 cases of esophageal candidiasis. Any patients with evidence of active, latent, or inadequately treated tuberculosis (TB) at screening were excluded from the studies, and background csDMARDs. Patients advancing to tofacitinib 5 mg BD after 3 or 6 months on placebo reported HAQ-DI improvements following advancement (Fig. 2). Observed HAQ-DI improvements from baseline with tofacitinib 5 mg BD were sustained over the remaining study periods (Fig. 2).

Across the 5 phase 3 studies, more patients receiving tofacitinib 5 mg BD achieved DAS-defined remission (DAS28-4 [ESR] <2.6) at month 3 compared with placebo-treated patients (Table 3). These differences were significant in ORAL Sync, ORAL Standard, and ORAL Step; because of the step-down procedure, significance was not declared in ORAL Scan.

In ORAL Standard, efficacy responses were numerically similar for patients receiving tofacitinib 5 mg BD or adalimumab 40 mg Q2W, although ORAL Standard was not designed for non-inferiority or superiority comparisons between tofacitinib and adalimumab (Figs. 1 and 2, Table 3).

Safety
As expected for active treatment arms, frequencies of AEs and SAEs were slightly higher with tofacitinib compared with placebo groups across all of the phase 3 studies between baseline and month 3 (patient-years of exposure for tofacitinib 5 mg BD vs. placebo for ORAL Solo, ORAL Sync, ORAL Standard, ORAL Scan, and ORAL Step: 30.1 vs. 15.0, 77.8 vs. 39.3, 49.0 vs. 26.5, 154.5 vs. 77.0, 16.5 vs. 16.4; Fig. 3). In total, 51.6% and 53.0% of patients receiving tofacitinib 5 mg BD and placebo, respectively, had AEs in the first 3 months. During this period, the most frequent AEs were diarrhea (2.2%–6.0%), headache (1.3%–5.6%), nasopharyngitis (1.6%–5.9%), and upper respiratory tract infection (2.8%–10.5%) for patients receiving tofacitinib 5 mg BD; and arthralgia (0.0%–3.8%), cough (0.0%–3.8%), peripheral edema (0.0%–3.8%), and upper respiratory tract infection (0.9%–4.9%) for placebo-treated patients. There were no frequent SAEs (all <1%) reported in either the tofacitinib 5 mg BD or placebo groups; SAEs were experienced by 2.9% of tofacitinib-treated patients and 4.1% of placebo-treated patients. During the first 3 months of treatment, 4.2% and 3.2% of tofacitinib- and placebo-treated patients discontinued because of AEs, respectively (Fig. 3). In ORAL Standard, tofacitinib- and adalimumab-treated patients reported generally similar AE rates: 52.0% for tofacitinib and 51.5% for adalimumab (patient-years of exposure to month 3 for tofacitinib 5 mg BD vs. adalimumab 40 mg Q2W: 49.0 vs. 49.8; Fig. 3). Although there were few SAEs or discontinuations due to AEs with both tofacitinib (5.9% and 6.9%, respectively) and adalimumab (2.5% and 4.9%, respectively), SAEs and discontinuations due to AEs were numerically higher with tofacitinib than adalimumab.

Overall, the most frequently reported infections for tofacitinib 5 mg BD and placebo across the full reported study periods (6 or 12 months) of the phase 3 studies were bronchitis (n = 14 and n = 10, respectively), herpes zoster (HZ; n = 5 and n = 2, respectively), influenza (n = 8 and n = 5, respectively), nasopharyngitis (n = 47 and n = 19, respectively), upper respiratory tract infection (n = 53 and n = 22, respectively), and urinary tract infection (n = 25 and n = 12, respectively) (patient-years of exposure for tofacitinib 5 mg BD vs. placebo: 1311.5 vs. 696.5). As expected for active treatment, SIEs were numerically more frequent in tofacitinib groups than in placebo groups; 29 patients receiving tofacitinib 5 mg BD and 3 placebo-treated patients reported SIEs. A total of 4 OIs were reported with tofacitinib 5 mg BD: 1 case each of disseminated HZ and Pneumocystis jirovecii pneumonia and 2 cases of esophageal candidiasis. Any patients with evidence of active, latent, or inadequately treated tuberculosis (TB) at screening were excluded from the studies, and
| Parameter | ORAL Solo | ORAL Sync | ORAL Standard | ORAL Scan | ORAL Step |
|-----------|-----------|-----------|---------------|-----------|-----------|
|           | Tofacitinib 5 mg BID (n = 243) | Placebo (n = 122) | Tofacitinib 5 mg BID (n = 315) | Placebo (n = 159) | Tofacitinib 5 mg BID (n = 204) | Placebo (n = 108) | Adalimumab 40 mg Q2W (n = 204) | Placebo (n = 104) | Tofacitinib 5 mg BID (n = 321) | Placebo (n = 160) | Tofacitinib 5 mg BID (n = 133) | Placebo (n = 132) |
| Population DMARD-IR | Female, n (%) | 207 (85.2) | 264 (83.8) | 174 (85.3) | 172 (85.2) | 209 (82.8) | 269 (83.8) | 268 (83.8) | 178 (85.6) | 113 (85.0) | 106 (80.3) |
|           | White, n (%) | 153 (63.0) | 88 (72.1) | 173 (54.9) | 92 (57.9) | 177 (52.2) | 75 (69.4) | 75 (69.4) | 172 (56.5) | 108 (81.2) | 112 (84.8) |
|           | Mean (SD) age, y | 52.2 (11.5) | 52.7 (11.7) | 53.0 (11.9) | 53.8 (13.7) | 52.6 (11.7) | 53.7 (11.6) | 53.7 (11.6) | 53.7 (11.6) | 55.4 (11.5) | 54.4 (11.3) |
|           | Mean (range) disease duration, y | 8.0 (0.2–42.3) | 8.1 (0.2–39.9) | 7.6 (0.3–39.0) | 8.0 (0.3–49.4) | 8.1 (0.2–36.3) | 8.9 (0.3–43.0) | 9.2 (0.4–43.5) | 8.9 (0.3–43.0) | 13.0 (1.2–55.0) | 11.3 (0.4–47.0) |
| Mean (SD) tender joint count | 29.0 (15.0) | 25.0 (15.3) | 25.0 (15.2) | 28.0 (15.0) | 27.0 (14.3) | 27.0 (15.3) | 24.0 (14.0) | 23.0 (13.1) | 28.0 (18.3) | 28.0 (16.7) |
| Mean (SD) swollen joint count | 16.0 (8.6) | 14.0 (10.3) | 14.0 (9.1) | 17.0 (8.8) | 17.0 (8.8) | 16.0 (8.7) | 14.0 (8.2) | 14.0 (8.4) | 16.0 (10.1) | 17.0 (10.7) |
| Mean (SD) mTSS | — | — | — | — | — | — | 31.1 (47.7) | 32.6 (41.8) | — | — |
| Mean (SD) HAQ-DI | 1.5 (0.7) | 1.4 (0.7) | 1.4 (0.7) | 1.5 (0.6) | 1.4 (0.7) | 1.5 (0.7) | 1.4 (0.7) | 1.3 (0.7) | 1.6 (0.7) | 1.6 (0.7) |
| Mean (SD) DAS28-4 (ESR) | 6.7 (0.9) | 6.3 (1.0) | 6.3 (0.9) | 6.6 (0.9) | 6.5 (0.9) | 6.4 (0.9) | 6.3 (1.0) | 6.3 (1.0) | 6.5 (1.0) | 6.5 (1.0) |
| Mean (SD) DAS28-3 (CRP) | 5.7 (0.9) | 5.2 (0.9) | 5.2 (0.9) | 5.4 (0.9) | 5.4 (0.9) | 5.3 (0.9) | 5.2 (0.9) | 5.16 (0.9) | 5.4 (1.0) | 5.4 (1.0) |

N numbers were slightly less than the N number stated based on data collection and availability.

CRP indicates C-reactive protein; DMARD, disease-modifying antirheumatic drug; SD, standard deviation.
| Outcome | ORAL Solo | ORAL Sync | ORAL Standard | ORAL Scan | ORAL Step |
|---------|-----------|-----------|---------------|-----------|-----------|
|         | Tofacitinib | Placebo | Tofacitinib | Placebo | Tofacitinib | Placebo | Adalimumab | Placebo | Tofacitinib | Placebo |
| ACR20, n (%) | 144 (59.8) | 32 (26.7) | 175 (56.3) | 43 (27.4) | 119 (60.7) | 28 (26.4) | 112 (56.3) | 174 (56.3) | 42 (27.3) | 55 (41.7) |
| ACR50, n (%) | 75 (31.1) | 15 (12.5) | 85 (27.3) | 15 (9.6) | 67 (34.2) | 7 (6.6) | 47 (23.6) | 89 (28.8) | 12 (7.8) | 35 (26.5) |
| ACR70, n (%) | 37 (15.4) | 7 (5.8) | 26 (8.4) | 3 (1.9) | 24 (12.2) | 2 (1.9) | 17 (8.5) | 33 (10.7) | 4 (2.6) | 18 (13.6) |

LS mean (SE) change from baseline:
- ACR20, n (%) | 0.12 (0.12) | 0.47 (0.16) |
- ACR50, n (%) | -0.50 (0.03) | -0.19 (0.05) |
- ACR70, n (%) | -0.46 (0.03) | -0.21 (0.04) |
- DAS28-4 (ESR) <2.6, n (%) | 13 (5.6) | 5 (4.4) |

Efficacy end points are measured at month 3, unless otherwise indicated; DAS28-4 (ESR) <2.6 is DAS-defined remission. Because of the step-down method, significance was not declared for mTSS, HAQ-DI, or DAS28-4 (ESR) in ORAL Scan. FAS, NRI for ACR and DAS end points; FAS, longitudinal model for HAQ-DI.

aPrimary end point of the study.
bSignificant difference versus placebo (p < 0.0001).
cSignificant difference versus placebo (p < 0.05).
dSignificant difference versus placebo (p < 0.001).
N numbers were slightly less than the N number stated based on data collection and availability.
ACR20/50/70 indicates proportion of patients achieving ≥20%, ≥50%, and ≥70% improvement in American College of Rheumatology criteria; DAS, disease activity score; FAS, full analysis set; LS, least squares; NRI, non-responder imputation; SE, standard error.
no cases of TB were reported in patients receiving tofacitinib 5 mg BID or placebo during any of the phase 3 studies.\textsuperscript{36}

Malignancies (excluding nonmelanoma skin cancer [NMSC]) were reported in 8 patients in the tofacitinib 5 mg BID groups across the full reported study periods (6 or 12 months) of the phase 3 studies (incidence rate, 0.55 [95% confidence interval, \(0.27–1.09\)); patient-years of exposure for tofacitinib 5 mg BID vs. placebo: 1311.5 vs. 696.5).\textsuperscript{31} Six patients in the tofacitinib 5 mg BID groups reported NMSC (incidence rate, 0.41 [95% confidence interval, \(0.19–0.92\)).\textsuperscript{31} Eight patients receiving tofacitinib 5 mg BID had more than 1 malignancy (1 patient had esophageal carcinoma and colon carcinoma, 1 patient had prostate cancer and
basal cell carcinoma, 3 patients had 2 basal cell carcinomas, 2 patients had 2 squamous cell carcinomas, and 1 patient had squamous cell carcinoma and basal cell carcinoma.31 Two patients receiving tofacitinib 5 mg BID were reported to have lymphoma, and 2 placebo-treated patients reported NMSC.31 In ORAL Standard, malignancy (excluding NMSC) was reported in 1 patient (lung cancer) receiving adalimumab 40 mg Q2W (199 patient-years of exposure).

Four cardiovascular events were reported across the full reported study periods (6 or 12 months) for patients receiving tofacitinib 5 mg BID (1 each of transient ischemic attack [ORAL Sync], cerebrovascular accident [ORAL Sync], angina pectoris...
[ORAL Scan], coronary artery disease [ORAL Scan]) and none in placebo-treated patients (patient-years of exposure for tofacitinib 5 mg BID vs. placebo: 1311.5 vs. 696.5). One patient receiving adalimumab 40 mg Q2W in ORAL Standard reported 3 cardiovascular events (myocardial infarction, cardiac arrest, myocardial ischemia; 199 patient-years of exposure).

For patients receiving tofacitinib 5 mg BID, 5 deaths occurred up to 30 days from the last dose of study drug; 2 further deaths were reported after this time (1311.5 patient-years of exposure). One death was considered treatment related (pneumonia n = 1), 4 were considered possibly treatment related (P. jirovecii n = 1, septic syndrome n = 1, acute respiratory distress and pneumonia n = 1, metastatic lung cancer n = 1), and 2 were considered unrelated to study treatment (traumatic brain injury n = 1, viral infection n = 1). One death was reported in the placebo groups (696.5 patient-years of exposure).

Across the 5 phase 3 studies, decreases from baseline in neutrophil and lymphocyte counts and increases in hemoglobin and lipid levels, relative to placebo, were observed by month 3 with tofacitinib 5 mg BID (297.23 patient-years of exposure) and stabilized thereafter. Dose-dependent decreases in neutrophil counts were seen with tofacitinib and adalimumab, with similar magnitudes of change, in ORAL Standard and stabilized for all treatment groups thereafter. Neutropenia was more frequently reported in tofacitinib groups than in placebo groups, although no life-threatening cases of neutropenia were reported, and no SIEs were associated with neutropenia. The frequency of occurrence of lymphopenia was similar between tofacitinib- and placebo-treated patients. One placebo-treated patient withdrew from ORAL Step because of decreased hemoglobin levels. Four patients receiving tofacitinib 5 mg BID had confirmed greater than 50% increase in serum creatinine from baseline. One patient

![Figure 3](http://www.jclinrheum.com)
in the placebo to tofacitinib 5 mg BID group discontinued because of this, with levels subsequently stabilizing.

**DISCUSSION**

A large clinical program comprising phase 3 data from more than 4000 patients resulted in the approval of tofacitinib for the treatment of RA in many countries at a 5-mg BID dose. In 5 phase 3 studies enrolling patients with various treatment histories (Table 1), tofacitinib 5 mg BID rapidly reduced the signs and symptoms of RA and improved physical function when administered as monotherapy or with background csDMARDs. Tofacitinib 5 mg BID provided clinically meaningful improvements, as well as clinical and functional superiority to placebo, in patients with prior DMARD-IR. The variety of treatment backgrounds in these phase 3 studies (i.e., MTX, csDMARD, TNF-bDMARDs, and non-TNF-bDMARDs) demonstrated that tofacitinib could be effective for patients with a range of treatment histories in clinical practice. Across the 5 phase 3 studies, patients who advanced to tofacitinib 5 mg BID after 3 or 6 months on placebo had improvements in efficacy following the switch. These phase 3 results are consistent with efficacy results from phase 2 trials of tofacitinib 5 mg BID in DMARD-IR patients. Tofacitinib 5 mg BID had numerically similar efficacy results to adalimumab with MTX in ORAL Standard. The objectives of the ORAL Standard study were to compare the efficacy of tofacitinib with placebo and to compare adalimumab with placebo. It was not powered to detect noninferiority or superiority between tofacitinib and adalimumab, but the inclusion of this active control group allowed estimates of the relative efficacy of tofacitinib.

Identified safety events up to month 3 (patient-years of exposure for tofacitinib 5 mg BID vs. placebo: 297.25 vs. 167) were consistent across the 5 studies and generally consistent with phase 2 trials of tofacitinib 5 mg BID in DMARD-IR patients, and LITE studies. The proportions of patients reporting AEs, SAEs, SIEs, and discontinuing due to AEs were numerically higher for tofacitinib than adalimumab in ORAL Standard. In the phase 3 studies, SIEs were generally more frequent with tofacitinib 5 mg BID than placebo (1311.5 vs. 696.5 patient-years of exposure, respectively), and rates were similar to those in phase 2 studies. A pooled analysis of infections across phase 2, phase 3, and LTE studies of tofacitinib found the overall SIE rate with tofacitinib (5 and 10 mg BID) to be 3.1 events per 100 patient-years. The SIE rate was 3.2 events per 100 patient-years for tofacitinib 5 mg BID versus 1.5 events per 100 patient-years for placebo from pooled phase 3 study data. Serious infection events have been reported in other tofacitinib studies (3, 5, and 10 mg BID), although where reported in the phase 3 studies, none of the moderate to severe neutropenia cases with tofacitinib 5 mg BID were associated with SIEs. Decreases in mean lymphocyte levels were observed in the phase 3 studies, and although not assessed in phase 3 studies, in LTE studies rates of SIEs were increased in patients with confirmed lymphocyte counts of less than 0.5 × 10^3/mm^3. It remains unclear whether lipid level changes associated with tofacitinib are associated with increases in infectious AE rates, although, where reported in the phase 3 studies, none of the moderate to severe neutropenia cases with tofacitinib 5 mg BID were associated with SIEs. Decreases in mean lymphocyte levels were observed in the phase 3 studies, and although not assessed in phase 3 studies, in LTE studies rates of SIEs were increased in patients with confirmed lymphocyte counts of less than 0.5 × 10^3/mm^3. It remains unclear whether lipid level changes associated with immune-modulatory therapy are associated with increases in cardiovascular risks or whether increases in cardiovascular events are due to RA. Cardiovascular event rates in tofacitinib LTE studies are similar to published csDMARD and bDMARD rates. Changes in serum creatinine and liver aminotransferase values were small and consistent across all groups in all 5 studies. Pooled analyses and LTE studies have shown that reported tofacitinib-associated changes in serum creatinine levels and liver transaminases are reversible. In addition, tofacitinib-related serum creatinine changes do not appear to be associated with acute renal failure or progressive worsening of renal function.

These studies are limited by the relatively short placebo-controlled period, making analysis and interpretation of differences between active treatment and placebo difficult. However, this is an inherent issue when active treatment cannot be reasonably withheld for ethical reasons. These phase 3 studies were also relatively short in duration compared with the chronic duration of RA; however, long-term tofacitinib safety and efficacy continue to be monitored in an ongoing LTE study, postmarketing surveillance, and analyses of real-world data. In addition, no specific screening methods were used to detect malignancies in any of these trials, so underlying malignancies may not be captured in the data. Patients who developed malignancies were required to discontinue, so it was not possible to assess
the risk of tofacitinib treatment on the development of additional malignancies.

Although we have observed and discussed similarities and differences in the safety and efficacy profiles of tofacitinib 5 mg BID to csDMARDs and bDMARDs reported in the literature, our comparisons are not based on head-to-head studies and should be interpreted with caution.

This comprehensive review of phase 3 data demonstrates that, in patients with DMARD-IR, tofacitinib 5 mg BID reduced the signs and symptoms of RA and improved physical function during the first 3 months of treatment. Improvements were sustained to month 6, similar to adalimumab with MTX in ORAL Standard and to other DMARDs across studies. Tofacitinib 5 mg BID demonstrated a consistent, manageable safety profile across the phase 3 studies. Patients should be monitored for AEs of special interest, including SIEs, OIs, malignancies and lymphomas, GI perforations, cardiovascular events, and changes in laboratory parameters. Monitoring of long-term tofacitinib safety and efficacy is ongoing in LTE studies, postmarketing surveillance, and analyses of real-world data.

**KEY POINTS**

- We performed a comprehensive review of phase 3 studies of tofacitinib 5 mg BID, the widely approved dose, in patients with moderate to severe RA and DMARD-IR.
- In phase 3 studies, tofacitinib 5 mg BID reduced the signs and symptoms of RA and improved physical function.
- Tofacitinib 5 mg BID demonstrated a consistent, manageable safety profile across the phase 3 studies.

**REFERENCES**

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. *Lancet*. 2010;376:1094–1108.
2. Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. *Am J Manag Care*. 2007;13(suppl 9):S237–S251.
3. Hochberg MC, Johnston SS, John AK. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. *Curr Med Res Opin*. 2008;24:469–480.
4. Breedveld F. The value of early intervention in RA—a window of opportunity. *Clin Rheumatol*. 2011;30(suppl 1):S33–S39.
5. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. *Ann Rheum Dis*. 2014;73:492–509.
6. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. *Arthritis Care Res (Hoboken)*. 2012;64:625–639.
7. Smolen JS, Aletaha D, Koeberl M, et al. New therapies for treatment of rheumatoid arthritis. *Lancet*. 2007;370:1861–1874.
8. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. *Arthritis Rheum*. 2004;50:1400–1411.
9. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. *N Engl J Med*. 2000;343:1594–1602.
10. Finckh A, Simard JF, Gabay C, et al. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. *Ann Rheum Dis*. 2006;65:746–752.
11. Agarwal SK, Glass RJ, Shadick NA, et al. Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. *J Rheumatol*. 2008;35:1737–1744.
12. Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. *Rheumatology (Oxford)*. 2012;51(suppl 5):v38–v47.
13. Egan PJ, Landvort KE, Alexander WS, et al. Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T cell activation. *J Clin Invest*. 2003;111:915–924.
14. Egwuagu CE. STAT3 in CD4+ T helper cell differentiation and inflammatory diseases. *Cytokine*. 2009;47:149–156.
15. Moyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. *J Inflamm (Lond)*. 2010;7:41.
16. Changelian PS, Moshinsky D, Kuhn CF, et al. The specificity of JAK3 kinase inhibitors. *Blood*. 2008;111:2155–2157.
17. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). *J Immunol*. 2011;186:4234–4243.
18. Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. *Arthritis Rheum*. 2012;64:617–629.
19. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. *Arthritis Rheum*. 2009;60:1895–1905.
20. Kremer JM, Cohen S, Wilkinson BE, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. *Arthritis Rheum*. 2012;64:970–981.
21. McNees IB, Kim HY, Lee SH, et al. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. *Ann Rheum Dis*. 2014;73:124–131.
22. Tanaka Y, Suzuki M, Nakamura H, et al. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. *Arthritis Care Res (Hoboken)*. 2011;63:1150–1158.
23. Wollenhaupt J, Silverfield J, Lee EB, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, long-term extension studies. *J Rheumatol*. 2014;41:837–852.
24. Yamanaka H, Tanaka Y, Takeuchi T, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis: a randomized trial. *Arthritis Care Res*. 2013;159:253–261.
25. Van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. *N Engl J Med*. 2012;367:508–519.
26. Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. *N Engl J Med*. 2014;370:2377–2386.
28. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367: 495–507.

29. Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381:451–460.

30. van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559–570.

31. Curtis JR, Lee EB, Kaplan IV, et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis. 2016;75: 831–841.

32. Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66: 2675–2684.

33. Winthrop KL, Park SH, Gul A, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1133–1138.

34. Cohen S, Radominski SC, Gomez-Reino JJ, et al. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:2924–2937.

35. Isaacs JD, Zuckerman A, Krishnaswami S, et al. Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials. Arthritis Res Ther. 2014;16(R158).

36. Winthrop KL, Novosad SA, Baddley JW, et al. Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Ann Rheum Dis. 2015;74: 2107–2116.

37. van Vollenhoven RF, Emery P, Bingham CO III, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72:1496–1502.

38. Schiff MH, Kremer JM, Jahrreis A, et al. Integrated safety in tocilizumab arthritis with an inadequate response to tumour necrosis factor inhibitors: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54:2368–2376.

39. Favaligi E, Desiati F, Atzeni F, et al. Serious infections during anti-TNF alpha treatment in rheumatoid arthritis patients. Autoimmun Rev. 2009;8:266–273.

40. Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatol (Oxford). 2011;50: 124–131.

41. Alahdieh S, Checchio T, Tensfeldt T, et al. Meta-analysis of malignancies, serious infections, and serious adverse events with tofacitinib and biologic treatment in rheumatoid arthritis clinical trials. Arthritis Rheum. 2012; 64(suppl 10): S726.

42. Winthrop KL, Curtis JR, Lindsey S, et al. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol. 2017;69:1960–1968.

43. Naganak EM, Johnson RW, Griffin DR, et al. Geographic and racial aspects of herpes zoster. J Med Virol. 2003;70(suppl 1):S20–S23.

44. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti–TNF-alpha agents. JAMA. 2009;301: 737–744.

45. McDonald JR, Zeringue AL, Caplan L, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis. 2009; 48:1364–1371.

46. Burmester GR, Mariette X, Montecucco C, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis. 2007;66: 732–739.

47. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098–1104.

48. Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 2004;50:372–379.

49. Brassard P, Kezouh A, Suissa S. Anti-TNF agents and the risk of tuberculosis. Clin Infect Dis. 2006;43:717–722.

50. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumour necrosis factor antagonists. Arthritis Rheum. 2005;52:1766–1772.

51. Seong SS, Choi CB, Woo JH, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol. 2007;34:706–711.

52. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of serious infections, and serious adverse events with tofacitinib and biologic treatment in rheumatoid arthritis clinical trials. Arthritis Rheum. 2012; 64(suppl 10): S726.

53. Balain B, Dzoln A, Sproux A, et al. Tuberculosis and infliximab treatment. National surveillance from January 1, 2000, through June 30, 2003 [in French]. Presse Med. 2005;34:353–357.

54. Sichiedis L, Settas L, Sypnatos D, et al. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis. 2006; 10:1127–1132.

55. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010;36:1185–1206.
63. Weinblatt ME, Moreland LW, Westhovens R, et al. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. *J Rheumatol.* 2013;40:787–797.

64. Simon TA, Smitten AL, Franklin J, et al. Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. *Ann Rheum Dis.* 2009;68:1819–1826.

65. Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. *Ann Rheum Dis.* 2013;72:517–524.

66. Bykerk VP, Cush J, Winthrop K, et al. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. *Ann Rheum Dis.* 2015;74:96–103.

67. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. *Lancet.* 2009;374:210–221.

68. Keystone EC, Genovese MC, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension. *J Rheumatol.* 2013;40:1097–1103.

69. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. *Arthritis Rheum.* 2007;56:2886–2895.

70. Askling J, Fahrbach K, Nordstrom B, et al. Cancer risk with tumor necrosis factor antagonists. *Pharmacoepidemiol Drug Saf.* 2011;20:119–130.

71. Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis during treatment with tumor necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. *Ann Rheum Dis.* 2011;70:1895–1904.

72. Mellemkjaer L, Linet MS, Gridley G, et al. Rheumatoid arthritis and cancer risk. *Eur J Cancer.* 1996;32A:1753–1757.

73. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. *J Rheumatol.* 2005;32:2130–2135.

74. Mariette X, Mattucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. *Ann Rheum Dis.* 2011;70:1895–1904.

75. Baechle E, Askling J, Rosenquist R, et al. Rheumatoid arthritis and malignant lymphomas. *Curr Opin Rheumatol.* 2004;16:254–261.

76. Baechle E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. *Arthritis Rheum.* 2006;54:692–701.

77. Curtis JR, Lee EB, Martin G, et al. Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme. *Clin Exp Rheumatol.* 2017;35:614–622.

78. Curtis JR, Xie F, Chen L, et al. The incidence of gastrointestinal perforations among rheumatoid arthritis patients. *Arthritis Rheum.* 2011;63:346–351.

79. Curtis JR, Lanas A, John A, et al. Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis. *Arthritis Care Res (Hoboken).* 2012;64:1819–1828.

80. Schulze-Koops H, Strand V, Nduaka C, et al. Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies. *Rheumatology (Oxford).* 2017;56:46–57.

81. Charles-Schoeman C, Wicker P, Gonzalez-Gay MA, et al. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. *Semin Arthritis Rheum.* 2016;46:261–271.

82. Harnett J, Curtis J, Gruben D, et al. Early experience with tofacitinib: results through 2 years of the GO-AFTER study extension. *J Rheumatol.* 2013;40:1097–1103.

83. Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. *Ann Rheum Dis.* 2009;68:460–469.

84. Isaacs J, Zuckerman A, Krishnaswami S, et al. Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials. *Arthritis Res Ther.* 2015;17:95.

85. Saiki O, Takao R, Naruse Y, et al. Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis. *J Rheumatol.* 2007;34:1997–2004.

86. Kremer JM, Kivitz AJ, Simon-Campos JA, et al. Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial. *Arthritis Res Ther.* 2015;17:95.

87. Harnett J, Curtis J, Gruben D, et al. Early experience with tofacitinib: treatment patterns in two US healthcare claims databases. *Ann Rheum Dis.* 2015;74:740.